| 吕晓冰 陈晓 李荣 王宏涛 聂玲.赖诺普利联合坎地沙坦治疗心力衰竭合并原发性高血压[J].现代生物医学进展英文版,2014,14(31):6135-6138. |
| 赖诺普利联合坎地沙坦治疗心力衰竭合并原发性高血压 |
| Clinical Observation on the Lisinopril plus Candesartan in the Treatment ofHeart Failure Combined with Essential Hypertension |
| |
| DOI： |
| 中文关键词: 赖诺普利 坎地沙坦 心力衰竭 高血压 联合治疗 |
| 英文关键词: Lisinopril Candesartan Heart failure Hypertension Combined therapy |
| 基金项目: |
|
| Hits: 746 |
| Download times: 331 |
| 中文摘要: |
| 目的：观察和评价赖诺普利联合坎地沙坦治疗心力衰竭(HF)合并原发性高血压(EH)的疗效。方法：将我院收治的EH 合并
HF患者69 例，在给予个体化治疗的基础上随机分为：A 组赖诺普利治疗组，B 组坎地沙坦治疗组，C 组赖诺普利和坎地沙坦联合
治疗组，三组疗程均为8 周。观察治疗前后的血压、心功能分级、BNP水平、心脏彩色多普勒及肝肾功检查。结果：与对照组比较，
联合组的总有效率明显增高，差异有统计学意义；治疗前后所有患者肝肾功能等生化指标未见明显变化。结论：赖诺普利与坎地
沙坦联合治疗心力衰竭合并原发性高血压的疗效明显优于单用赖诺普利或坎地沙坦的疗效，且安全性好，值得广泛推广和应用。 |
| 英文摘要: |
| Objective:To observe and evaluate the efficacy and safety of clinical observation on the Lisinopril plus Candesartan
in the treatment of heart failure(HF)combined with essential hypertension(EH).Methods:69 patients with heart failure and hypertension
were enrolled and randomly divided into three groups on the basis of different medications: The patients in group A were treated by the
Lisinopril for 8 weeks, while the patients in groupB were treated by the Candesartan for 8 weeks and the patients in group C were treated
by the Lisinopril combined with the Candesartan for 8 weeks. Then the heart function which referred to the blood pressure, the NYHA
classification, the level of brain natriuretic peptide (BNP), the echocardiography and the function of liver and kidney of patients were
observed and compared among the three groups before and after the treatment.Results:Compared with group A and group B, the total
effective rate of group C was improved obviously (P<0.05), and there was no significant difference in biochemical indexes before and
after treatment between the three groups (P>0.05).Conclusion:The efficacy of Lisinopril combined with Candesartan in the treatment of
heart failure and hypertension was much better than that of the single dosage of Lisinopril or Candesartan, which was worthy of being
promoted in clinical trials. |
|
View Full Text
View/Add Comment Download reader |
| Close |
